Commure has 6 close competitors: Abridge, Alloy Therapeutics, HeartFlow.
Sector, valuation and status for each competitor.
company profile›
competitor›
competitor›
competitor›
competitor›A private valuation and a public market cap share one column; each row names its basis and date.
CommureAbridgeHeartFlowInnovaccerNeuralinkAI-native healthcare operations platform providing ambient clinical documentation, patient intake and revenue-cycle automation to health systems, headquartered in Mountain View, California. Merged with Athelas in October 2023.
Commure competes with 6 companies here: Abridge, Alloy Therapeutics, HeartFlow, HistoSonics, Innovaccer, Neuralink.
Commure was last valued at $7B (post-money, May 2026). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
The routes section explains what is realistically available for a company at this stage.
No. Commure is a private company; its shares do not trade on a public exchange.
The last valuation is $7B (post-money, May 2026).
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
